HK1087338A1 - USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM - Google Patents

USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM

Info

Publication number
HK1087338A1
HK1087338A1 HK06107698.4A HK06107698A HK1087338A1 HK 1087338 A1 HK1087338 A1 HK 1087338A1 HK 06107698 A HK06107698 A HK 06107698A HK 1087338 A1 HK1087338 A1 HK 1087338A1
Authority
HK
Hong Kong
Prior art keywords
medicament
agent
preparation
fat metabolism
regulating fat
Prior art date
Application number
HK06107698.4A
Other languages
English (en)
Inventor
Patrick D Fourney
Volkmar Guenzler-Pukall
Stephen J Klaus
Al Y Lin
Thomas B Neff
Todd W Seeley
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of HK1087338A1 publication Critical patent/HK1087338A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06107698.4A 2002-12-06 2006-07-10 USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM HK1087338A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43135102P 2002-12-06 2002-12-06
US47672603P 2003-06-06 2003-06-06
US47633103P 2003-06-06 2003-06-06
US10/729,167 US7618940B2 (en) 2002-12-06 2003-12-04 Fat regulation
PCT/US2003/038690 WO2004052285A2 (en) 2002-12-06 2003-12-05 Fat regulation

Publications (1)

Publication Number Publication Date
HK1087338A1 true HK1087338A1 (en) 2006-10-13

Family

ID=32512564

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107698.4A HK1087338A1 (en) 2002-12-06 2006-07-10 USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM

Country Status (9)

Country Link
US (2) US7618940B2 (no)
EP (1) EP1578431A4 (no)
JP (1) JP2006514113A (no)
AU (1) AU2003298926C1 (no)
CA (1) CA2506159C (no)
HK (1) HK1087338A1 (no)
IL (1) IL168323A (no)
NO (1) NO20053116L (no)
WO (1) WO2004052285A2 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN1816527A (zh) * 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN101374815B (zh) * 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
US7625927B2 (en) * 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20080050740A1 (en) * 2006-06-23 2008-02-28 Cassidy Pamela M Nutritional and Exercise Plan Based On A Person's Individual Genetic APO E Genotype
HUE041300T2 (hu) 2006-06-26 2019-05-28 Akebia Therapeutics Inc Prolilhidroxiláz inhibitorok és alkalmazási eljárások
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2111399A2 (en) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7569726B2 (en) * 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CA2683956C (en) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2685219C (en) * 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2009073669A1 (en) * 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
JP6022769B2 (ja) 2008-04-28 2016-11-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール
CN102264740B (zh) * 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2010093727A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
US8796263B2 (en) 2010-08-13 2014-08-05 Janssen Pharmaceutica Nv 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
US8921389B2 (en) 2011-02-02 2014-12-30 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
WO2012105630A1 (ja) * 2011-02-03 2012-08-09 国立大学法人広島大学 脂質代謝関連疾患の検査方法、ならびに脂質代謝関連疾患の予防および／または治療剤の評価方法
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (no) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
CN104053439B (zh) 2011-10-25 2016-08-24 詹森药业有限公司 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂
US20150018384A1 (en) * 2012-03-09 2015-01-15 Fibrogen, Inc. Treatment for high cholesterol
AU2013229922B2 (en) 2012-03-09 2017-09-28 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
LT2872488T (lt) 2012-07-16 2018-10-25 Fibrogen, Inc. Kristalinės prolilhidroksilazės inhibitoriaus formos
US9340511B2 (en) * 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
ES2786924T3 (es) 2013-06-06 2020-10-14 Fibrogen Inc Formulaciones farmacéuticas que comprenden un inhibidor de hidroxilasa del HIF
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ773901A (en) 2015-04-01 2024-07-26 Akebia Therapeutics Inc Compositions and methods for treating anemia
US20180306788A1 (en) * 2015-04-07 2018-10-25 President And Fellows Of Harvard College Compositions and methods for modulating hydroxylation of acc2 by phd3
CN109180580B (zh) 2016-02-28 2021-01-12 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基化合物及包含该化合物的组合物及其用途
CA3058352A1 (en) * 2017-03-29 2018-10-04 Eduardo Munoz Blanco Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US20210322084A1 (en) * 2018-10-12 2021-10-21 Miraki Innovation Think Tank Llc Cold solution for fat reduction
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE878480C (de) * 1951-05-16 1953-06-05 Richard Abr Herder Fa Drehmomentschluessel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
GB9402857D0 (en) * 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0878480A1 (en) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller A method for the improvement of neuronal regeneration
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE69820288T2 (de) 1997-10-24 2004-10-21 Fibrogen Inc Phenanthrolin-derivate
US5916898A (en) * 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
US6200974B1 (en) * 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
JP2001525173A (ja) * 1997-12-04 2001-12-11 ジェンザイム・コーポレーション 遺伝子発現を誘導するための組成物および方法
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
WO2003045440A1 (en) 2001-11-28 2003-06-05 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein
CN1602360A (zh) 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
JP2004083570A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 低酸素応答誘導剤およびその製法
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation

Also Published As

Publication number Publication date
US20100168152A1 (en) 2010-07-01
AU2003298926A1 (en) 2004-06-30
JP2006514113A (ja) 2006-04-27
AU2003298926C1 (en) 2010-02-04
NO20053116L (no) 2005-09-05
US8202834B2 (en) 2012-06-19
CA2506159C (en) 2011-05-24
NO20053116D0 (no) 2005-06-24
EP1578431A2 (en) 2005-09-28
US20040235082A1 (en) 2004-11-25
EP1578431A4 (en) 2008-04-23
IL168323A (en) 2011-07-31
WO2004052285A2 (en) 2004-06-24
WO2004052285A3 (en) 2004-09-02
CA2506159A1 (en) 2004-06-24
AU2003298926B2 (en) 2009-09-03
US7618940B2 (en) 2009-11-17

Similar Documents

Publication Publication Date Title
HK1087338A1 (en) USE OF AN AGENT THAT STABILIZES HIFa FOR PREPARATION OF MEDICAMENT FOR REGULATING FAT METABOLISM
HK1089107A1 (en) Delivery of therapeutic compounds to the brain and other tissues
EP1673104A4 (en) DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE
EP1638605A4 (en) DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
IL175529A0 (en) Methods and compositions for the treatment of metabolic disorders
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
ZA200504558B (en) Compounds for the treatment of metabolic disorders
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
HK1073997A1 (en) Administration of agents for the treatment of inflammation
IL165820A0 (en) Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL165397A0 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
EP1372726A4 (en) METHOD FOR REDUCING FAT BY ADMINISTRATING ADIPONECTIN
AU2003286728A8 (en) Compounds for the treatment of metabolic disorders
PL1740204T3 (pl) Lecznicze zastosowanie alfa-mannozydazy
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
IL172101A0 (en) Use of indazole derivatives for the treatment of neuropathic pain
EP1677745A4 (en) NITRON COMPOUND PRODRUGS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF HUMAN DISEASES
AU2003266210A8 (en) Use of mas-compounds for treating diseases associated with lipid metabolism
GB0304871D0 (en) Formulation for treatment of paralizing pain stiffness
AU2003213349A1 (en) Therapeutic agent for pain
AU2003224561A1 (en) Use of dhea for treatment of female hypopituitarism
SI1646387T1 (sl) Uporaba indazolnih derivatov za zdravljenje nevropaticne bolecine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131205